Zentalis Pharmaceuticals, Inc. (ZNTL)
| Previous close | 11.11 |
| Open | 11.63 |
| Bid | 11.76 x 200 |
| Ask | 11.90 x 100 |
| Day's range | 11.51 - 12.11 |
| 52-week range | 9.56 - 31.46 |
| Volume | |
| Avg. volume | 827,759 |
| Market cap | 842.217M |
| Beta (5Y monthly) | 1.73 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -4.47 |
| Earnings date | 08 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 34.40 |
GlobeNewswireZentalis Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NEW YORK and SAN DIEGO, May 01, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancer, today announced that on May 1, 2024, the Compensation Committee of Zentalis’ Board of Directors granted non-qualified stock options to purchase an aggregate of 91,200 shares of the Company’s common stock to three newly
- GlobeNewswire
Zentalis Pharmaceuticals to Highlight Preclinical Data Demonstrating that WEE1 Inhibitor Azenosertib Exerts Synergistic Anti-tumor Activity with KRAS(G12C) Inhibitors at AACR Annual Meeting 2024
Research supports azenosertib’s potential to be highly synergistic in combination with KRAS targeted cancer therapeutics, creating an additional large opportunity to combine with other standard of care agentsNEW YORK and SAN DIEGO, April 02, 2024 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, will pr
Simply Wall St.Zentalis Pharmaceuticals, Inc.'s (NASDAQ:ZNTL) Intrinsic Value Is Potentially 98% Above Its Share Price
Key Insights The projected fair value for Zentalis Pharmaceuticals is US$30.67 based on 2 Stage Free Cash Flow to...
